Patents Examined by Catherine S Hibbert
  • Patent number: 10557160
    Abstract: Recombinant bacterial cells are provided that comprise a stable non-canonical amino acid translation pathway. In some aspects, the bacteria comprise nucleic acids encoding a non-canonical amino acid translation pathway (e.g., a tRNA for incorporation of a non-canonical amino acid, such selenocysteine); a marker polypeptide that includes the non-canonical amino acid. Recombinant tRNA and selection marker coding sequences are likewise provided.
    Type: Grant
    Filed: December 15, 2016
    Date of Patent: February 11, 2020
    Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Andrew D. Ellington, Ross Thyer
  • Patent number: 10550162
    Abstract: Compositions and methods for genetically modifying the production levels of nicotine and other alkaloids in plants are provided.
    Type: Grant
    Filed: June 9, 2017
    Date of Patent: February 4, 2020
    Assignee: UNIVERSITY OF VIRGINIA PATENT FOUNDATION
    Inventors: Michael Paul Timko, Paul J Rushton, Marta Tatiana Bokowiec
  • Patent number: 10550384
    Abstract: The present invention relates to genetically modified bacteria and methods of optimizing genetically modified bacteria for the production of a metabolite.
    Type: Grant
    Filed: February 26, 2014
    Date of Patent: February 4, 2020
    Assignee: President and Fellows of Harvard College
    Inventors: George M. Church, Srivatsan Raman, Noah D. Taylor, Jameson Rogers
  • Patent number: 10538770
    Abstract: The present invention relates functional ligands to target molecules, particularly to functional nucleic acids and modifications thereof, and to methods for simultaneously generating, for example, numerous different functional biomolecules, particularly to methods for generating numerous different functional nucleic acids against multiple target molecules simultaneously. The present invention further relates to functional ligands which bind with affinity to target molecules such as chikungunya viral proteins, such as chikungunya envelope protein E1.
    Type: Grant
    Filed: September 21, 2017
    Date of Patent: January 21, 2020
    Assignee: Base Pair Biotechnologies, Inc.
    Inventor: George W. Jackson
  • Patent number: 10526618
    Abstract: RNA guided Cas9 gene drives and method for their use are disclosed.
    Type: Grant
    Filed: June 3, 2016
    Date of Patent: January 7, 2020
    Assignee: President and Fellows of Harvard College
    Inventors: Kevin M. Esvelt, Andrea L. Smidler
  • Patent number: 10519454
    Abstract: The disclosure provided herewith relates to a Campylobacter jejuni CRISPR/CAS system-derived RGEN and a use thereof.
    Type: Grant
    Filed: January 31, 2017
    Date of Patent: December 31, 2019
    Assignee: TOOLGEN INCORPORATED
    Inventors: Eun Ji Kim, Seok Joong Kim
  • Patent number: 10487125
    Abstract: The present invention relates to a nucleic acid construct comprising: a nucleic acid sequence encoding an ice structuring protein (ISP) comprising the sequence set out in SEQ ID NO: 1 or a sequence at least 80% identical thereto or comprising the sequence set out in amino acids 21 to 261 of SEQ ID NO: 1 or a sequence at least 80% identical thereto; and, linked operably thereto, control sequences permitting expression of the nucleic acid sequence in a filamentous fungal host cell. The construct may be used in a method for the production of an ISP, wherein the ISP is expressed in a filamentous fungal host cell.
    Type: Grant
    Filed: December 2, 2014
    Date of Patent: November 26, 2019
    Assignee: DSM IP ASSETS B.V.
    Inventors: René Marcel De Jong, Petrus Jacobus Theodorus Dekker
  • Patent number: 10488420
    Abstract: This disclosure relates to methods of diagnosing and predicting renal disease, using one, two, or more biomarkers, including sTN-FR1, sTNFR2, sFAS, TNF, and IL-6.
    Type: Grant
    Filed: September 21, 2017
    Date of Patent: November 26, 2019
    Assignee: Joslin Diabetes Center, Inc.
    Inventors: Monika A. Niewczas, Andrzej S. Krolewski
  • Patent number: 10480032
    Abstract: The present disclosure relates to a novel use of EI24, and provides a novel use of EI24 involved in the improvement of EGFR-TKI drug resistance by inhibiting IGF-1R signaling. According to the present disclosure, the presence or absence of resistance to anti-cancer drugs may be determined by detecting an expression level of EI24. In addition, resistance to anti-cancer drugs may be inhibited, delayed, or improved using EI24 or an activating agent thereof. Moreover, by regulating a pathway of EI24-mediated resistance to anti-cancer drugs, the efficacy of existing anti-cancer drugs may be enhanced, and resistance to anti-cancer drugs may be inhibited, delayed, or improved.
    Type: Grant
    Filed: March 14, 2017
    Date of Patent: November 19, 2019
    Assignee: University-Industry Foundation, Yonsei University
    Inventors: Han Woong Lee, Jung-Min Choi, Byoung Chul Cho, Yu-Ra Choi, Ji-Young Jang, Hye Ryun Kim
  • Patent number: 10472631
    Abstract: The invention relates to the use of microRNA 29 and precursors and mimics thereof for the modulation of tendon injury and the biomechanical properties of tendon. In particular, the invention derives from the finding that synthesis of type 1 collagen in tenocytes is less sensitive to miR-29 than is synthesis of type 3 collagen, thus enabling the balance between the collagen subtypes to be modulated in favour of type 1 collagen, mitigating reduction in biomechanical properties during healing.
    Type: Grant
    Filed: January 25, 2018
    Date of Patent: November 12, 2019
    Inventors: Derek Stewart Gilchrist, Neal Lindsay Millar
  • Patent number: 10457922
    Abstract: The present disclosure provides engineered Class 1 Type I CRISPR-Cas (Cascade) systems that comprise multi-protein effector complexes, nucleoprotein complexes comprising Type I CRISPR-Cas subunit proteins and nucleic acid guides, polynucleotides encoding Type I CRISPR-Cas subunit proteins, and guide polynucleotides. Also, disclosed are methods for making and using the engineered Class 1 Type I CRISPR-Cas systems of the present invention.
    Type: Grant
    Filed: May 22, 2019
    Date of Patent: October 29, 2019
    Assignee: Caribou Biosciences, Inc.
    Inventors: Peter Sean Cameron, Sanne Eveline Klompe, Samuel Henry Sternberg
  • Patent number: 10443061
    Abstract: An object is to provide a signal peptide that can secrete a heterologous polypeptide with high efficiency outside the bacterial cell in a bacterium of the genus Bifidobacterium, an expression cassette that can secrete a heterologous polypeptide with high efficiency outside the bacterial cell, a heterologous polypeptide expression vector, a bacterium of the genus Bifidobacterium capable of secreting a heterologous polypeptide. Means for attaining the object is a bacterium of the genus Bifidobacterium transformed by a vector having an expression cassette sequentially comprising a promoter DNA functioning in a bacterium of the genus Bifidobacterium, a DNA encoding the secretory signal peptide, a DNA encoding a scFv antibody having an antitumor activity, and a terminator DNA functioning in the bacterium of the genus Bifidobacterium; and capable of secreting the scFv antibody with high efficiency outside the bacterial cell.
    Type: Grant
    Filed: April 17, 2015
    Date of Patent: October 15, 2019
    Assignee: Anaeropharma Science, Inc.
    Inventors: Koichi Koseki, Takeshi Masaki, Koichiro Shioya, Hitomi Shimizu, Masao Tsukamoto, Satoshi Kobayashi, Tomio Matsumura, Yuko Shimatani
  • Patent number: 10435717
    Abstract: The present invention provides genetically modified eukaryotic host cells that produce isoprenoid precursors or isoprenoid compounds. A subject genetically modified host cell comprises increased activity levels of one or more of mevalonate pathway enzymes, increased levels of prenyltransferase activity, and decreased levels of squalene synthase activity. Methods are provided for the production of an isoprenoid compound or an isoprenoid precursor in a subject genetically modified eukaryotic host cell. The methods generally involve culturing a subject genetically modified host cell under conditions that promote production of high levels of an isoprenoid or isoprenoid precursor compound.
    Type: Grant
    Filed: October 2, 2017
    Date of Patent: October 8, 2019
    Assignee: The Regents of the University of California
    Inventors: Jay D. Keasling, James Kirby, Eric M. Paradise
  • Patent number: 10428316
    Abstract: The present invention relates to immortalized chicken embryo fibroblasts, to cell cultures comprising such immortalized cells, to vaccines comprising such cells, to methods for the propagation of avian viruses on such cells, and to methods for the preparation of such cells and such vaccines.
    Type: Grant
    Filed: December 3, 2015
    Date of Patent: October 1, 2019
    Assignee: Intervet Inc.
    Inventor: Jaap Kool
  • Patent number: 10421971
    Abstract: Compositions, kits and methods for treating cancer in a subject in need thereof are disclosed involving one or more genes the suppression of which renders the cancer chemosensitive and/or radiosensitive.
    Type: Grant
    Filed: October 24, 2014
    Date of Patent: September 24, 2019
    Inventors: Liufu Deng, Yang-xin Fu, Nikolai Khodarev, Ralph Weichselbaum
  • Patent number: 10421948
    Abstract: The present invention provides a method for increasing the expression of MAFA in cells expressing markers characteristic of the pancreatic endocrine lineage comprising the steps of culturing the cells expressing markers characteristic of the pancreatic endocrine lineage in medium comprising a sufficient amount of a cyclin-dependent kinase inhibitor to cause an increase in expression of MAFA.
    Type: Grant
    Filed: August 22, 2017
    Date of Patent: September 24, 2019
    Assignee: Janssen Biotech, Inc.
    Inventors: Alireza Rezania, Benjamin Fryer
  • Patent number: 10407666
    Abstract: This disclosure provides modified cytosine deaminases (CDs). The disclosure further relates to cells and vector expressing or comprising such modified CDs and methods of using such modified CDs in the treatment of disease and disorders.
    Type: Grant
    Filed: August 8, 2017
    Date of Patent: September 10, 2019
    Assignee: Tocagen Inc.
    Inventors: Harry E. Gruber, Douglas J. Jolly, Omar D. Perez, Christopher R. Logg
  • Patent number: 10407728
    Abstract: The invention concerns gene signatures obtained from microvesicles and a method of applying these gene signatures in helping to determine a biological condition. The determination of a biological condition may aid, for example, the diagnosis, prognosis, and therapy treatment selection for disease in a subject.
    Type: Grant
    Filed: July 6, 2015
    Date of Patent: September 10, 2019
    Assignee: The General Hospital Corporation
    Inventors: Mikkel Noerholm, Johan Karl Olov Skog, Xandra O. Breakefield, Bob Carter
  • Patent number: 10393732
    Abstract: The screening method of the present invention is useful for screening drugs such as insulin secretagogues having an insulin secretagogue activity with minimized side effects (hypoglycemia induction, etc.). The transformant in which a polynucleotide encoding the fusion protein used for the screening method is introduced, the screening kit comprising the transformant, etc. are also useful for screening excellent drugs.
    Type: Grant
    Filed: September 15, 2017
    Date of Patent: August 27, 2019
    Assignee: JNC Corporation
    Inventor: Satoshi Inouye
  • Patent number: 10375938
    Abstract: A method of modulating some or all copies of a gene in a cell is provided including introducing into a cell one or more ribonucleic acid (RNA) sequences that comprise a portion that is complementary to all or a portion of each of the one or more target nucleic acid sequences, and a nucleic acid sequence that encodes a Cas protein and maintaining the cells under conditions in which the Cas protein is expressed and the Cas protein binds and modulates the one or more target nucleic acid sequences in the cell.
    Type: Grant
    Filed: February 5, 2018
    Date of Patent: August 13, 2019
    Assignee: President and Fellows of Harvard College
    Inventors: George M. Church, Luhan Yang, Marc Guell